Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 6
2004 2
2005 4
2006 12
2007 4
2009 1
2010 1
2011 1
2012 2
2013 2
2014 2
2015 4
2016 4
2017 8
2018 4
2019 2
2020 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting.
Quagliariello V, Gennari A, Jain SA, Rosso F, Iaffaioli RV, Barbarisi A, Barbarisi M, Tirelli N. Quagliariello V, et al. Among authors: iaffaioli rv. Mater Sci Eng C Mater Biol Appl. 2021 Dec;131:112475. doi: 10.1016/j.msec.2021.112475. Epub 2021 Oct 12. Mater Sci Eng C Mater Biol Appl. 2021. PMID: 34857264 Free article.
Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab.
Quagliariello V, Vecchione R, De Capua A, Lagreca E, Iaffaioli RV, Botti G, Netti PA, Maurea N. Quagliariello V, et al. Among authors: iaffaioli rv. Int J Nanomedicine. 2020 Jul 9;15:4859-4876. doi: 10.2147/IJN.S245170. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32764923 Free PMC article.
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial.
Piccirillo MC, Avallone A, Carlomagno C, Maiello E, Rosati G, Alabiso O, Nasti G, De Placido S, Latiano TP, Bilancia D, Ottaiano A, De Stefano A, Romano C, Silvestro L, Nappi A, Cassata A, Giordano P, Iaffaioli RV, Normanno N, Perrone F, Daniele B. Piccirillo MC, et al. Among authors: iaffaioli rv. Clin Colorectal Cancer. 2020 Dec;19(4):270-276. doi: 10.1016/j.clcc.2020.05.009. Epub 2020 May 29. Clin Colorectal Cancer. 2020. PMID: 32631788 Clinical Trial.
Resveratrol in Cancer Patients: From Bench to Bedside.
Berretta M, Bignucolo A, Di Francia R, Comello F, Facchini G, Ceccarelli M, Iaffaioli RV, Quagliariello V, Maurea N. Berretta M, et al. Among authors: iaffaioli rv. Int J Mol Sci. 2020 Apr 22;21(8):2945. doi: 10.3390/ijms21082945. Int J Mol Sci. 2020. PMID: 32331450 Free PMC article. Review.
Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.
Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V. Barbarisi M, et al. Among authors: iaffaioli rv. Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28. Phytother Res. 2019. PMID: 30924205
Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.
Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, Iaffaioli RV, Botti G, Netti PA, Maurea N. Quagliariello V, et al. Among authors: iaffaioli rv. Nutrients. 2018 Sep 14;10(9):1304. doi: 10.3390/nu10091304. Nutrients. 2018. PMID: 30223482 Free PMC article.
Corrigendum to "Association of Ozone with 5-Fluorouracil and Cisplatin in Regulation of Human Colon Cancer Cell Viability: In Vitro Anti-Inflammatory Properties of Ozone in Colon Cancer Cells Exposed to Lipopolysaccharides".
Simonetti V, Quagliariello V, Giustetto P, Franzini M, Iaffaioli RV. Simonetti V, et al. Among authors: iaffaioli rv. Evid Based Complement Alternat Med. 2018 Apr 30;2018:3297906. doi: 10.1155/2018/3297906. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 29855623 Free PMC article.
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.. Pinto C, et al. Among authors: iaffaioli rv. Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30. Future Oncol. 2018. PMID: 29846100 Clinical Trial.
61 results